Posted by Michael Wonder on 17 May 2019
Health technology assessment challenges in oncology: 20 years of Value in Health
16 May 2019 - Oncology treatments have changed from chemotherapies to targeted therapies and more recently immuno-oncology.
This has posed special challenges in the field of health technology assessment (HTA): capturing quality of life (QOL) associated with toxicity due to chemotherapy, crossover upon progression in targeted therapy trials, and survival extrapolation for immuno-oncology drugs.
A review was undertaken of oncology articles published in ViH from May 1998 to August 2018. Full-length articles published in ViH with the keywords “oncology,” “cancer,” “h(a)ematology,” and “malignancy” were included for review. Conference abstracts were excluded.
